xylem inc. - XYL

XYL

Close Chg Chg %
129.78 1.62 1.24%

Closed Market

131.39

+1.62 (1.24%)

Volume: 1.75M

Last Updated:

Feb 6, 2025, 3:59 PM EDT

Company Overview: xylem inc. - XYL

XYL Key Data

Open

$130.14

Day Range

129.00 - 131.63

52 Week Range

113.26 - 146.08

Market Cap

$31.54B

Shares Outstanding

242.95M

Public Float

241.30M

Beta

1.07

Rev. Per Employee

N/A

P/E Ratio

35.56

EPS

$2.33

Yield

110.93%

Dividend

$0.40

EX-DIVIDEND DATE

Feb 18, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

1.41M

 

XYL Performance

1 Week
 
5.95%
 
1 Month
 
15.26%
 
3 Months
 
5.67%
 
1 Year
 
5.73%
 
5 Years
 
56.08%
 

XYL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 22
Full Ratings ➔

About xylem inc. - XYL

Xylem, Inc. engages in the design, manufacture, and application of engineered technologies for the water industry. It operates through the following business segments: Water Infrastructure, Applied Water, and Measurement and Control Solutions. The Water Infrastructure segment focuses on the transportation, treatment and testing of water. The Applied Water segment encompasses the uses of water and focuses on the commercial, residential, and industrial end markets. The Measurement and Control Solutions segment focuses on developing technology solutions that enable intelligent use and conservation of critical water and energy resources as well as analytical instrumentation used in the testing of water. The company was founded in 2011 and is headquartered in Washington, DC.

XYL At a Glance

Xylem, Inc.
301 Water Street SE
Washington, District of Columbia 20003
Phone 1-202-869-9150 Revenue 8.56B
Industry Industrial Machinery Net Income 890.00M
Sector Producer Manufacturing 2024 Sales Growth 16.221%
Fiscal Year-end 12 / 2025 Employees N/A
View SEC Filings

XYL Valuation

P/E Current 35.564
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 31.786
Price to Sales Ratio 3.30
Price to Book Ratio 2.649
Price to Cash Flow Ratio 22.368
Enterprise Value to EBITDA 17.995
Enterprise Value to Sales 3.432
Total Debt to Enterprise Value 0.069

XYL Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 5.133
Total Asset Turnover 0.525

XYL Liquidity

Current Ratio 1.762
Quick Ratio 1.334
Cash Ratio 0.483

XYL Profitability

Gross Margin 37.515
Operating Margin 12.509
Pretax Margin 12.696
Net Margin 10.395
Return on Assets 5.459
Return on Equity 8.554
Return on Total Capital 7.031
Return on Invested Capital 7.025

XYL Capital Structure

Total Debt to Total Equity 18.944
Total Debt to Total Capital 15.927
Total Debt to Total Assets 12.22
Long-Term Debt to Equity 18.709
Long-Term Debt to Total Capital 15.729
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Xylem Inc. - XYL

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
5.20B 5.54B 7.37B 8.56B
Sales Growth
+6.71% +6.58% +32.95% +16.22%
Cost of Goods Sold (COGS) incl D&A
3.22B 3.44B 4.64B 5.35B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
245.00M 236.00M 436.00M 562.00M
Depreciation
118.00M 111.00M 193.00M 258.00M
Amortization of Intangibles
127.00M 125.00M 243.00M 304.00M
COGS Growth
+5.75% +6.71% +35.13% +15.23%
Gross Income
1.98B 2.10B 2.72B 3.21B
Gross Income Growth
+8.32% +6.37% +29.41% +17.91%
Gross Profit Margin
+38.07% +37.99% +36.98% +37.51%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.38B 1.44B 1.99B 2.14B
Research & Development
204.00M 206.00M 232.00M 230.00M
Other SG&A
1.18B 1.23B 1.76B 1.91B
SGA Growth
+3.98% +4.12% +38.13% +7.64%
Other Operating Expense
- - - -
-
Unusual Expense
(14.00M) 140.00M 46.00M 62.00M
EBIT after Unusual Expense
610.00M 525.00M 689.00M 1.01B
Non Operating Income/Expense
(2.00M) (6.00M) 25.00M 122.00M
Non-Operating Interest Income
- 7.00M 16.00M 28.00M
Equity in Earnings of Affiliates
- - - 9.00M
-
Interest Expense
97.00M 79.00M 79.00M 44.00M
Interest Expense Growth
- +1.04% -18.56% -44.30%
Gross Interest Expense
97.00M 79.00M 79.00M 44.00M
Interest Capitalized
- - - -
-
Pretax Income
511.00M 440.00M 635.00M 1.09B
Pretax Income Growth
+79.30% -13.89% +44.32% +71.18%
Pretax Margin
+9.83% +7.94% +8.62% +12.70%
Income Tax
84.00M 85.00M 26.00M 197.00M
Income Tax - Current - Domestic
- 21.00M 93.00M 19.00M
Income Tax - Current - Foreign
- 53.00M 56.00M 86.00M
Income Tax - Deferred - Domestic
- (2.00M) (55.00M) (57.00M)
Income Tax - Deferred - Foreign
- 12.00M (9.00M) (22.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - 9.00M
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
427.00M 355.00M 609.00M 890.00M
Minority Interest Expense
- - - -
-
Net Income
427.00M 355.00M 609.00M 890.00M
Net Income Growth
+68.11% -16.86% +71.55% +46.14%
Net Margin Growth
+8.21% +6.41% +8.27% +10.39%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
427.00M 355.00M 609.00M 890.00M
Preferred Dividends
- - - -
-
Net Income Available to Common
427.00M 355.00M 609.00M 890.00M
EPS (Basic)
2.369 1.9698 2.8063 3.6686
EPS (Basic) Growth
+67.99% -16.85% +42.47% +30.73%
Basic Shares Outstanding
180.25M 180.22M 217.01M 242.60M
EPS (Diluted)
2.3523 1.9616 2.7913 3.65
EPS (Diluted) Growth
+67.71% -16.61% +42.30% +30.76%
Diluted Shares Outstanding
181.53M 180.98M 218.18M 243.50M
EBITDA
841.00M 901.00M 1.17B 1.63B
EBITDA Growth
+12.43% +7.13% +29.97% +39.45%
EBITDA Margin
+16.18% +16.26% +15.90% +19.07%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 149.786
Number of Ratings 22 Current Quarters Estimate 0.96
FY Report Date 03 / 2025 Current Year's Estimate 4.657
Last Quarter’s Earnings 1.18 Median PE on CY Estimate N/A
Year Ago Earnings 4.27 Next Fiscal Year Estimate 5.241
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 14 17 16
Mean Estimate 0.96 1.14 4.66 5.24
High Estimates 1.01 1.21 4.74 5.51
Low Estimate 0.93 1.07 4.58 4.90
Coefficient of Variance 2.11 3.05 1.11 2.87

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 12 12 12
OVERWEIGHT 2 2 3
HOLD 7 7 7
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Xylem Inc. - XYL

Date Name Shares Transaction Value
Jan 6, 2025 Rodney O. Aulick SVP & President, WSS 74,301 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $116.02 per share 8,620,402.02
Jun 12, 2024 Geri McShane VP, Controller & CAO 5,067 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $75.18 per share 380,937.06
Jun 12, 2024 Geri McShane VP, Controller & CAO 5,814 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $74.07 per share 430,642.98
Jun 12, 2024 Geri McShane VP, Controller & CAO 3,536 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $138.63 per share 490,195.68
Jun 12, 2024 Geri McShane VP, Controller & CAO 747 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 12, 2024 Geri McShane VP, Controller & CAO 1,019 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Rodney O. Aulick SVP & President, WSS 21,800 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Rodney O. Aulick SVP & President, WSS 76,287 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $139.01 per share 10,604,655.87
Jun 5, 2024 Claudia S. Toussaint SVP, CPSO 4,204 Bona fide gift 0.00
May 21, 2024 Jeanne M. Beliveau-Dunn Director 8,454 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2024 Lisa Glatch Director 8,755 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2024 Earl R. Ellis Director 2,988 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2024 Uday Yadav Director 7,326 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2024 Lila Alexey Tretikov Director 7,380 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2024 Mark D. Morelli Director 4,974 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2024 Jerome A. Peribere Director 4,570 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2024 Victoria Dux Harker Director 21,835 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2024 Robert F. Friel Director 33,926 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 Claudia S. Toussaint SVP, CPSO 6,488 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $127.94 per share 830,074.72
Mar 6, 2024 Claudia S. Toussaint SVP, CPSO 7,543 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $127.94 per share 965,051.42

Xylem Inc. in the News